Use of CBD Oil for Reducing the Negative Emotional Impact of COVID-19: A Randomized Clinical Trial
Ph.D Caitlin M Fischer, Michael J Telch
The COVID-19 pandemic heightened mental health challenges, highlighting the need for accessible and scalable interventions. This four-arm randomized placebocontrolled clinical trial compared the relative efficacy of different CBD oil formulations in reducing self-reported COVID-19 stress reactions, including anxiety, depression, anger, substance use, and sleep disturbance. After a baseline symptom assessment, participants (N = 148) were randomly assigned to one of four conditions: (1) 300 mg of pure CBD isolate, (2) 300 mg of broad-spectrum CBD, (3) 300 mg of full spectrum CBD, or (4) placebo oil. Participants took daily doses of their assigned treatment oil and recorded symptoms, adherence, and side effects in a nightly log over the four-week treatment period. We hypothesized that all three active CBD formulations would result in greater reductions in stress-related symptoms compared to placebo. Additionally, based on preclinical research on the entourage effect, we predicted that full spectrum CBD would outperform CBD isolate. Additional aims included exploring potential moderators of treatment response (e.g., baseline stress reactions) and assessing the safety and tolerability of daily CBD dosing.
TREATMENT DOSING ACROSS CONDITIONS Table 8 presents the average doses across treatment conditions both overall and by treatment week (Weeks 1-4). Averages were calculated by first calculating each participant's average daily dose, followed by averaging these values within each treatment condition. Daily dose averages by condition are illustrated in Figure 8 .
APPENDICES Appendix A: PROMIS Emotional Distress -Anxiety -Short Form 8a In the past 7 days… Never (1)
Rarely (2) Sometimes ( 3 ) Often ( 4 ) Always ( 5 )
Appendix G: COVID-19 Impact Survey The following questions ask about how COVID-19 has affected your life. How has COVID-19 affected your job? •
Appendix I: Medication Effects Form People may have different reactions to taking CBD products. While sleepiness or sedation may be the most common reaction, we've included a list of other less common reactions below. If you feel that any of these reactions are strong enough to interfere with your ability to function such as driving a car or operating heavy machinery, please refrain from those activities until these reactions start to subside. Please select the severity rating that best fits your experience in the past 24 hours.
Not present (0) Mild ( 1 ) Moderate ( 2 ) Dry mouth Trembling Blurred vision Headaches Heart racing or pounding Poor sleep Tingling or numbness Forgetfulness Ringing in your ears Poor concentration Delayed urination Frequent urination Weight gain Difficulty achieving orgasm..
References
Analyses, None
Bates, Mächler, Bolker, Walker, Fitting linear mixed-effects models Usinglme4, Journal of Statistical Software,
doi:10.18637/jss.v067.i01Ben-Shabat, Fride, Sheskin, Tamiri, Rhee et al., An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity, European Journal of Pharmacology,
doi:10.1016/s0014-2999(98)00392-6Bergamaschi, Queiroz, De Oliveira, De Martinis, Kapczinski et al., Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients, Neuropsychopharmacology,
doi:10.1038/npp.2011Berthold, Kamble, Kanumuri, Kuntz, Senetra et al., Comparative pharmacokinetics of commercially available cannabidiol isolate, broad-spectrum, and full-spectrum products, European Journal of Drug Metabolism and Pharmacokinetics,
doi:10.1007/s13318-023-00839-3Bisogno, Hanus, De Petrocellis, Tchilibon, Ponde et al., Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide: Cannabidiol, VR1 receptors and anandamide inactivation, British Journal of Pharmacology,
doi:10.1038/sj.bjp.0704327Bonaccorso, Ricciardi, Zangani, Chiappini, Schifano, Cannabidiol (CBD) use in psychiatric disorders: A systematic review, Neurotoxicology,
doi:10.1016/j.neuro.2019.08.002Bueno-Notivol, Gracia-García, Olaya, Lasheras, López-Antón et al., Prevalence of depression during the COVID-19 outbreak: A meta-analysis of community-based studies, International Journal of Clinical and Health Psychology: IJCHP,
doi:10.1016/j.ijchp.2020.07.007Campos, Ferreira, Guimarães, Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors, Journal of Psychiatric Research,
doi:10.1016/j.jpsychires.2012.08.012Campos, Moreira, Gomes, Del Bel, Guimarães, Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders, Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences,
doi:10.1098/rstb.2011.0389Chagas, Crippa, Zuardi, Hallak, Machado-De-Sousa et al., Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats, Journal of Psychopharmacology,
doi:10.1177/0269881112474524Chu, Marwaha, Sanvictores, Awosika, Ayers, Physiology, stress reaction
Chye, Christensen, Solowij, Yücel, The endocannabinoid system and cannabidiol's promise for the treatment of substance use disorder, Frontiers in Psychiatry,
doi:10.3389/fpsyt.2019.00063Cippitelli, Bilbao, Gorriti, Navarro, Massi et al., The anandamide transport inhibitor AM404 reduces ethanol self-administration: Alcoholism and anandamide transport, The European Journal of Neuroscience,
doi:10.1111/j.1460-9568.2007.05665.xCoelho, Vieira, Araújo-Junior, Lopes-Martins, Santos et al., The impact of cannabidiol treatment on anxiety disorders: A systematic review of randomized controlled clinical trials, Life,
doi:10.3390/life14111373Cook, Kallen, Cella, Crane, Eldadah et al., The patient reported outcomes measurement information system (PROMIS) perspective on: universally-relevant vs. disease-attributed scales
Crippa, Derenusson, Ferrari, Wichert-Ana, Duran et al., Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report, Journal of Psychopharmacology,
doi:10.1177/0269881110379283Crippa, Zuardi, Guimarães, Campos, De Lima Osório et al., Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical Trial, JAMA Network Open,
doi:10.1001/jamanetworkopen.2021.20603Czeisler, Lane, Petrosky, Wiley, Christensen et al., Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic -United States, June 24-30, 2020, MMWR. Morbidity and Mortality Weekly Report,
doi:10.15585/mmwr.mm6932a1De Almeida, Devi, Diversity of molecular targets and signaling pathways for CBD, Pharmacology Research & Perspectives,
doi:10.1002/prp2.682De Petrocellis, Cascio, Di Marzo, The endocannabinoid system: a general view and latest additions: Endocannabinoid biochemistry updated, British Journal of Pharmacology,
doi:10.1038/sj.bjp.0705666Devane, Hanuš, Breuer, Pertwee, Stevenson et al., Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science,
doi:10.1126/SCIENCE.1470919Di Marzo, Bifulco, De Petrocellis, The endocannabinoid system and its therapeutic exploitation, Nature Reviews. Drug Discovery,
doi:10.1038/nrd1495Elms, Shannon, Hughes, Lewis, Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series, Journal of Alternative and Complementary Medicine,
doi:10.1089/acm.2018.0437Elsaid, Kloiber, Le Foll, Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings, Progress in Molecular Biology and Translational Science,
doi:10.1016/bs.pmbts.2019.06.005Espejo-Porras, Fernández-Ruiz, Pertwee, Mechoulam, García, Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors, Neuropharmacology,
doi:10.1016/j.neuropharm.2013.07.024Ferber, Namdar, Hen-Shoval, Eger, Koltai et al., The "Entourage Effect": Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders, Current Neuropharmacology,
doi:10.2174/1570159X17666190903103923Freeman, Cannabidiol treatment cannabis use disorder: phase 2a, doubleblind, placebo-controlled, randomized, adaptive Bayesian trial, Lancet Psychiatry
Freeman, Petrilli, Lees, Hindocha, Mokrysz et al., How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review, Neuroscience and Biobehavioral Reviews,
doi:10.1016/j.neubiorev.2019.09.036Gallily, Yekhtin, Hanuš, Overcoming the bell-shaped dose-response of cannabidiol by using Cannabis extract enriched in cannabidiol, Pharmacology & Pharmacy,
doi:10.4236/PP.2015.62010Gonzalez-Cuevas, Martin-Fardon, Kerr, Stouffer, Parsons et al., Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle, Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology,
doi:10.1038/s41386-018-0050-8Green, Macleod, SIMR: an R package for power analysis of generalized linear mixed models by simulation, Methods in Ecology and Evolution,
doi:10.1111/2041-210X.12504Hagen, Lai, Goldmann, Trends in negative emotions throughout the COVID-19 pandemic in the United States, Public Health,
doi:10.1016/j.puhe.2022.08.009Hartmann, Lisboa, Sonego, Coutinho, Gomes et al., Cannabidiol attenuates aggressive behavior induced by social isolation in mice: Involvement of 5-HT1A and CB1 receptors, Progress in Neuro-Psychopharmacology & Biological Psychiatry,
doi:10.1016/j.pnpbp.2019.109637Hermush, Ore, Stern, Mizrahi, Fried et al., Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial, Frontiers in Medicine,
doi:10.3389/fmed.2022.951889Hsiao, Yi, Li, Chang, Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats, Neuropharmacology,
doi:10.1016/j.neuropharm.2011.08.013Hurd, Yoon, Manini, Hernandez, Olmedo et al., Early phase in the development of cannabidiol as a treatment for addiction: Opioid relapse takes initial center stage, Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics,
doi:10.1007/s13311-015-0373-7Iffland, Grotenhermen, An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies, Cannabis and Cannabinoid Research,
doi:10.1089/can.2016.0034Jahrami, Bahammam, Bragazzi, Saif, Faris et al., Sleep problems during the COVID-19 pandemic by population: a systematic review and meta-analysis, Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine,
doi:10.5664/jcsm.8930Jurkus, Day, Guimarães, Lee, Bertoglio et al., Cannabidiol Regulation of Learned Fear: Implications for Treating Anxiety-Related Disorders, Frontiers in Pharmacology,
doi:10.3389/fphar.2016.00454Kesner, Lovinger, Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings, Journal of Neurochemistry,
doi:10.1111/jnc.15369Khan, Naveed, Mian, Fida, Raafey et al., The therapeutic role of Cannabidiol in mental health: a systematic review, Journal of Cannabis Research,
doi:10.1186/s42238-019-0012-yLee, Bertoglio, Guimarães, Stevenson, Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders: CBD regulation of fear and drug reward processing, British Journal of Pharmacology,
doi:10.1111/bph.13724Leon, Olfson, Portera, Farber, Sheehan, Assessing psychiatric impairment in primary care with the Sheehan Disability Scale, International Journal of Psychiatry in Medicine,
doi:10.2190/T8EM-C8YH-373N-1UWDLin, Lee, Yang, Serotonin and mental disorders: a concise review on molecular neuroimaging evidence, Clinical Psychopharmacology and Neuroscience: The Official Scientific Journal of the Korean College of Neuropsychopharmacology,
doi:10.9758/cpn.2014.12.3.196Linares, Zuardi, Pereira, Queiroz, Mechoulam et al., Cannabidiol presents an inverted U-shaped doseresponse curve in a simulated public speaking test, Revista Brasileira de Psiquiatria,
doi:10.1590/1516-4446-2017-0015Linge, Jiménez-Sánchez, Campa, Pilar-Cuéllar, Vidal et al., Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors, Neuropharmacology,
doi:10.1016/j.neuropharm.2015.12.017Maestrini, Hui, Welsh, Restricted maximum likelihood estimation in generalized linear mixed models
Maioli, Mattoteia, Amin, Minassi, Caprioglio, Cannabinol: History, syntheses, and biological profile of the greatest "minor" cannabinoid, Plants,
doi:10.3390/plants11212896Marshall, Lewis-Fernandez, Blanco, Simpson, Lin et al., A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults, Depression and Anxiety,
doi:10.1002/da.20176Mcewen, Bowles, Gray, Hill, Hunter et al., Mechanisms of stress in the brain, Nature Neuroscience,
doi:10.1038/nn.4086Mckee, Hmidan, Crocker, Lam, Meyer et al., Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials, Journal of Psychiatric Research,
doi:10.1016/j.jpsychires.2021.05.044Mechoulam, Ben-Shabat, Hanus, Ligumsky, Kaminski et al., Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors, Biochemical Pharmacology,
doi:10.1016/0006-2952(95)00109-dMeissner, Cascella, Cannabidiol (CBD) in Clinical Care
Morgan, Das, Joye, Curran, Kamboj, Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings, Addictive Behaviors,
doi:10.1016/j.addbeh.2013.03.011Murillo-Rodríguez, The role of the CB1 receptor in the regulation of sleep, Progress in Neuro-Psychopharmacology & Biological Psychiatry,
doi:10.1016/j.pnpbp.2008.04.008Patel, Hill, Cheer, Wotjak, Holmes, The endocannabinoid system as a target for novel anxiolytic drugs, Neuroscience and Biobehavioral Reviews,
doi:10.1016/j.neubiorev.2016.12.033Paulus, Billieux, Benyamina, Karila, Cannabidiol in the context of substance use disorder treatment: A systematic review, Addictive Behaviors,
doi:10.1016/j.addbeh.2022.107360Peng, Fan, An, Ni, Huang et al., A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD), Basic & Clinical Pharmacology & Toxicology,
doi:10.1111/bcpt.13710Pilkonis, Choi, Reise, Stover, Riley et al., Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS®): depression, anxiety, and anger, Assessment,
doi:10.1177/1073191111411667Pilkonis, Yu, Colditz, Dodds, Johnston et al., Item banks for alcohol use from the Patient-Reported Outcomes Measurement Information System (PROMIS): use, consequences, and expectancies, Drug and Alcohol Dependence,
doi:10.1016/j.drugalcdep.2012.11.002Pilkonis, Yu, Dodds, Johnston, Lawrence et al., Item banks for substance use from the Patient-Reported Outcomes Measurement Information System (PROMIS(®)): Severity of use and positive appeal of use, Drug and Alcohol Dependence,
doi:10.1016/j.drugalcdep.2015.09.008Resstel, Tavares, Lisboa, Joca, Corrêa et al., 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats, British Journal of Pharmacology,
doi:10.1111/j.1476-5381.2008.00046.xRusso, Guy, A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol, Medical Hypotheses,
doi:10.1016/j.mehy.2005.08.026Réus, Stringari, Ribeiro, Luft, Abelaira et al., Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala, Acta Neuropsychiatrica,
doi:10.1111/j.1601-5215.2011.00579.xSaleska, Bryant, Kolobaric, D'adamo, Colwell et al., The safety and comparative effectiveness of nonpsychoactive cannabinoid formulations for the improvement of sleep: A doubleblinded, randomized controlled trial, Journal of the American Nutrition Association,
doi:10.1080/27697061.2023.2203221Santabárbara, Lasheras, Lipnicki, Bueno-Notivol, Pérez-Moreno et al., Prevalence of anxiety in the COVID-19 pandemic: An updated meta-analysis of community-based studies, Progress in Neuro-Psychopharmacology & Biological Psychiatry,
doi:10.1016/j.pnpbp.2020.110207Schafer, Yucel, Computational strategies for multivariate linear mixed-effects models with missing values, Journal of Computational and Graphical Statistics: A Joint Publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America,
doi:10.1198/106186002760180608Shannon, Lewis, Lee, Hughes, Cannabidiol in Anxiety and Sleep: A Large Case Series, The Permanente Journal,
doi:10.7812/TPP/18-041Sheehan, Harnett-Sheehan, Raj, None, SDS. International Clinical Psychopharmacology
Sheehan, Scale, Sds), None
Shin, Liberzon, The neurocircuitry of fear, stress, and anxiety disorders, Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology,
doi:10.1038/npp.2009Sholler, Schoene, Spindle, Therapeutic efficacy of cannabidiol (CBD): A review of the evidence from clinical trials and human laboratory studies, Current Addiction Reports,
doi:10.1007/s40429-020-00326-8Side, None
Skelley, Deas, Curren, Ennis, Use of cannabidiol in anxiety and anxiety-related disorders, Journal of the American Pharmacists Association: JAPhA,
doi:10.1016/j.japh.2019.11.008Stack, Wheate, Moloney, Abelev, Barlow et al., The effectiveness and adverse events of cannabidiol and tetrahydrocannabinol used in the treatment of anxiety disorders in a PTSD subpopulation: An interim analysis of an observational study, The Journal of Pharmacy Technology: JPT: Official Publication of the Association of Pharmacy Technicians,
doi:10.1177/87551225231180796Stanley, Ferretti, Bonn-Miller, Irons, A double-blind, randomized, placebo-controlled test of the effects of cannabidiol on experiences of test anxiety among college students, Cannabis and Cannabinoid Research,
doi:10.1089/can.2022.0062Stern, De Carvalho, Bertoglio, Takahashi, Effects of Cannabinoid Drugs on Aversive or Rewarding Drug-Associated Memory Extinction and Reconsolidation, Neuroscience,
doi:10.1016/j.neuroscience.2017.07.018Taylor, Crockett, Tayo, Checketts, Sommerville, Abrupt withdrawal of cannabidiol (CBD): A randomized trial, Epilepsy & Behavior: E&B,
doi:10.1016/j.yebeh.2020.106938Taylor, Gidal, Blakey, Tayo, Morrison, A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects, CNS Drugs,
doi:10.1007/s40263-018-0578-5Telch, COVID-19 Impact Scale
Viudez-Martínez, García-Gutiérrez, Fraguas-Sánchez, Torres-Suárez, Manzanares, Effects of cannabidiol plus naltrexone on motivation and ethanol consumption: Cannabidiol and naltrexone in alcohol use disorder, British Journal of Pharmacology,
doi:10.1111/bph.14380White, A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential, Journal of Clinical Pharmacology,
doi:10.1002/jcph.1387Xi, Peng, Li, Song, Zhang et al., Brain cannabinoid CB₂ receptors modulate cocaine's actions in mice, Nature Neuroscience,
doi:10.1038/nn.2874Younger, Gandhi, Hubbard, Mackey, Development of the Stanford Expectations of Treatment Scale (SETS): a tool for measuring patient outcome expectancy in clinical trials, Clinical Trials,
doi:10.1177/1740774512465064Yu, Buysse, Germain, Moul, Stover et al., Development of short forms from the PROMIS TM sleep disturbance and Sleep-Related Impairment item banks, Behavioral Sleep Medicine,
doi:10.1080/15402002.2012.636266Zoppi, Pérez Nievas, Madrigal, Manzanares, Leza et al., Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinflammation, Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology,
doi:10.1038/npp.2010.214Zuardi, Rodrigues, Silva, Bernardo, Hallak et al., Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life, Frontiers in Pharmacology,
doi:10.3389/fphar.2017.00259DOI record:
{
"DOI": "10.26153/TSW/61958",
"URL": "https://repositories.lib.utexas.edu/handle/2152/134636",
"abstract": "The COVID-19 pandemic heightened mental health challenges, highlighting the need for accessible and scalable interventions. This four-arm randomized placebo-controlled clinical trial compared the relative efficacy of different CBD oil formulations in reducing self-reported COVID-19 stress reactions, including anxiety, depression, anger, substance use, and sleep disturbance. After a baseline symptom assessment, participants (N = 148) were randomly assigned to one of four conditions: (1) 300 mg of pure CBD isolate, (2) 300 mg of broad-spectrum CBD, (3) 300 mg of full spectrum CBD, or (4) placebo oil. Participants took daily doses of their assigned treatment oil and recorded symptoms, adherence, and side effects in a nightly log over the four-week treatment period. We hypothesized that all three active CBD formulations would result in greater reductions in stress-related symptoms compared to placebo. Additionally, based on preclinical research on the entourage effect, we predicted that full spectrum CBD would outperform CBD isolate. Additional aims included exploring potential moderators of treatment response (e.g., baseline stress reactions) and assessing the safety and tolerability of daily CBD dosing. Results showed a significant effect of time across all groups but no significant interaction between time and treatment condition, indicating that reductions in stress reactions were similar across the CBD and placebo conditions at post-treatment and one-week follow-up. A marginal interaction between baseline distress and group was observed in the broad-spectrum group, suggesting those participants with higher baseline distress may have experienced greater improvements compared to the placebo (p = 0.079) and CBD full spectrum (p = 0.085) conditions. However, these findings should be interpreted with caution due to their marginal significance level. Last, most participants (73.68%) assigned to any of the three active CBD oil conditions reported no side effects. Consistent with the literature, most reported side effects were mild to moderate, and only four participants discontinued due to these concerns. Across the active conditions, 13 participants (13.68%) endorsed severe side effects, with 10 of these participants assigned to the CBD full spectrum condition. These findings add to the literature on CBD’s safety profile. Additional well-powered research is needed to examine CBD’s potential in attenuating stress reactions.",
"author": [
{
"family": "Fischer",
"given": "Caitlin Mary"
},
{
"literal": "0000-0001-8559-962X"
}
],
"categories": [
"Entourage effect",
"COVID-19 stress symptoms",
"CBD full spectrum",
"CBD broad-spectrum",
"RCT",
"Placebo-controlled",
"CBD oil",
"CBD isolate"
],
"contributor": [
{
"family": "of Texas at Austin",
"given": "The University"
},
{
"family": "of Texas at Austin",
"given": "The University"
},
{
"family": "Telch",
"given": "Michael Joseph"
}
],
"id": "https://doi.org/10.26153/tsw/61958",
"issued": {
"date-parts": [
[
2025,
8
]
]
},
"publisher": "The University of Texas at Austin",
"title": "Use of CBD oil for reducing the negative emotional impact of COVID-19 : a randomized clinical trial",
"type": "thesis"
}
